Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reversal of Ticagrelor and Aspirin Effects Using Normal Platelets
NCT03005704Unknown
- Sponsor
- Hamilton Health Sciences
- Start
- Jan 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ticagrelor in platelet dysfunction (PFD) (2 arms), sponsored by Hamilton Health Sciences. Primary endpoint: Reversal of platelet inhibition at 5 days. Status: unknown.
02
Drugs
ticagrelor
03
Conditions
platelet dysfunction (PFD)
Beyond the preview
Go deeper on NCT03005704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03005704.